Daré's custom blend of topical sildenafil cream, containing 3.6%, demonstrated good tolerance levels at all tested strengths during the clinical trial, showing minimal systemic absorption. The company is actively progressing to move its Sildenafil Cream towards FDA's 505(b)(2) regulatory approval process while simultaneously introducing DARE to PLAY™ Sildenafil Cream, a compounded 503B version based on their exclusive sildenafil cream formulation.